Pfizer Inc. (NYSE:PFE) Shares Purchased by 180 Wealth Advisors LLC

180 Wealth Advisors LLC grew its holdings in shares of Pfizer Inc. (NYSE:PFE) by 3.1% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 28,489 shares of the biopharmaceutical company’s stock after acquiring an additional 857 shares during the period. 180 Wealth Advisors LLC’s holdings in Pfizer were worth $791,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in PFE. Stokes Capital Advisors LLC acquired a new stake in Pfizer during the first quarter valued at approximately $203,000. Lincoln Capital Corp acquired a new position in Pfizer in the first quarter worth $261,000. Vanguard Capital Wealth Advisors increased its stake in Pfizer by 4.2% during the first quarter. Vanguard Capital Wealth Advisors now owns 10,217 shares of the biopharmaceutical company’s stock valued at $284,000 after purchasing an additional 412 shares during the last quarter. Edge Wealth Management LLC raised its holdings in shares of Pfizer by 2.0% during the first quarter. Edge Wealth Management LLC now owns 260,180 shares of the biopharmaceutical company’s stock worth $7,220,000 after purchasing an additional 5,121 shares during the period. Finally, Cardinal Capital Management lifted its position in shares of Pfizer by 13.9% in the 1st quarter. Cardinal Capital Management now owns 88,811 shares of the biopharmaceutical company’s stock worth $2,465,000 after buying an additional 10,863 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Trading Up 1.4 %

Shares of NYSE:PFE traded up $0.38 during midday trading on Thursday, reaching $27.80. The company had a trading volume of 27,944,899 shares, compared to its average volume of 40,970,031. The company has a fifty day simple moving average of $27.81 and a two-hundred day simple moving average of $27.69. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.78 and a current ratio of 1.05. The firm has a market cap of $157.53 billion, a price-to-earnings ratio of -458.26, a price-to-earnings-growth ratio of 1.10 and a beta of 0.70. Pfizer Inc. has a 1-year low of $25.20 and a 1-year high of $37.80.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 EPS for the quarter, beating the consensus estimate of $0.56 by $0.26. Pfizer had a negative net margin of 0.56% and a positive return on equity of 8.64%. The business had revenue of $14.88 billion during the quarter, compared to the consensus estimate of $13.87 billion. During the same quarter in the prior year, the firm earned $1.23 EPS. The firm’s quarterly revenue was down 19.5% on a year-over-year basis. Research analysts predict that Pfizer Inc. will post 2.38 earnings per share for the current year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 3rd. Shareholders of record on Friday, July 26th will be paid a $0.42 dividend. The ex-dividend date is Friday, July 26th. This represents a $1.68 annualized dividend and a yield of 6.04%. Pfizer’s dividend payout ratio is presently -2,799.53%.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on PFE shares. Argus downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research report on Wednesday. Morgan Stanley upped their price target on shares of Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research report on Thursday, May 2nd. Finally, BMO Capital Markets reiterated an “outperform” rating and issued a $36.00 price objective (up from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Ten analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat.com, Pfizer presently has an average rating of “Hold” and an average target price of $35.86.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.